One Hotel Drive,

Boston,

MA,

US,

ZIP: 02128

Phone: +1 617 455 4188

With no room for error in the highly competitive ADC market and no going back after you have selected your target, it is vital that drug developers optimally triangulate the linker-payload, target and indication to develop an ADC that can have the biggest impact on patients.

Recent exciting developments in linker-payload technologies and clinical efficacy in low-expressed tumors have propelled this conversation to the forefront of mind. We are at the cusp of seeing clinical improvements on previously validated targets, witnessing success on targets where previous ADCs have failed and engaging novel targets, widening the application of ADCs beyond what was thought.

The 2nd ADC Target Selection Summit will provide you an A-Z coverage of the key considerations that ADC developers are making when it comes to target selection including how to think about the payload and target holistically, understand expression profiles, and how proteomic and bioinformatic technologies can deepen our understanding of targets going forward.

Don't miss your one-stop shop to gain exclusive insights as ADC enthusiasts with backgrounds in target ID and validation, cancer biology and drug discovery come together to address core challenges in the target selection process.

Join 80+ peers from across the ADC landscape to transform your target selection strategies to ensure you are maximizing the therapeutic window of your ADC and improving patients outcomes.

URLs: 
Tickets: https://go.evvnt.com/1261856-2?pid=1052
Brochure: https://go.evvnt.com/1261856-3?pid=1052

Prices:
Drug Developer - Conference + Workshop Day: USD 3897.00,
Drug Developer - Conference Only: USD 2899.00,
Service Provider - Conference + Workshop Day: USD 4697.00,
Service Provider - Conference Only: USD 3499.00,
Academic - Conference + Workshop Day: USD 3297.00,
Academic - Conference Only: USD 2499.00

Jagath Reddy Junutula, President, Chief Executive Officer and Co-Founder, Aarvik Therapeutics, Yu Shen, Director, Oncology Discovery, AbbVie, Adrian Hobson, Senior Research Fellow, Drug Discovery Science and Technology Antibody-Drug Conjugates, AbbVie, Jixin Wang, Associate Director, Oncology Bioinformatics, AstraZeneca, John Lambert, Consultant, Attager Consulting, Rakesh Dixit, Chief Executive Officer, Bionavigen, Sayumi Yamazoe, Senior Principal Scientist, Bristol-Myers Squibb, Seema Kantak, Senior Vice President, Biotherapeutics, Exelixis, Christopher Shelton, Scientific Director, Tumor Cell Targeting Research Unit, GlaxoSmithKline, Aniko Palfi, Director, Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ed Ha, Head, ADC Innovation, Iksuda Therapeutics, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Thomas Nittoli, Senior Director, R and D Chemistry, Regeneron, John DaSilva, Associate Director, Oncology and Immuno-Oncology, Regeneron, Robert Lawrence, Senior Scientist, Seagen, Annette Vogl, Director, Biology and Translational Research, Tubulis GmbH, Jamie Rich, Director, Antibody- Drug Conjugate Technology and Therapeutic Development, Zymeworks